Related by context. All words. (Click for frequent words.) 72 SPIRIT FIRST 71 BRIM3 71 ENDEAVOR III 70 ILLUMINATE 69 BCIRG 69 viral kinetic 69 pivotal bioequivalence 69 DASISION 69 dose escalation clinical 69 Phase Ib clinical 69 randomized Phase III 69 Phase Ib study 69 NO# [002] 68 randomized Phase IIb 68 CAMMS# 68 phase IIa 68 RIBBON 68 phase Ib 68 Phase IIIb clinical 68 CALGB 68 SABCS 68 ToGA 68 MERLIN TIMI 68 phase IIb clinical 67 SUCCEED trial 67 PERSEUS 67 NSABP 67 PRIMO CABG 67 axitinib 67 multicentre randomized 67 ABCSG 67 ORAL Sync 67 Prostate AdenoCarcinoma Treatment 67 SPIRIT IV 67 PFO migraine 67 AIM HIGH 67 APEX AMI trial 67 MAGE A3 ASCI 67 oral ridaforolimus 66 sipuleucel T 66 Phase IIb III 66 CLARITY study 66 phase IIIb 66 ENDEAVOR IV 66 ongoing Phase 1b 66 TEMSO 66 Sorafenib HCC Assessment 66 CUSTOM III 66 phase IIa clinical 66 EVEREST II 66 LUX Lung 66 GetGoal Phase III 66 CARE HF 66 multicenter Phase II 66 Phase III psoriasis 66 PROSTVAC TM 66 placebo controlled Phase III 66 Phase 1a clinical 66 TAXUS ATLAS 66 STRIDE PD 66 Phase III VISTA 66 HCV SPRINT 65 multicenter phase 65 multicenter Phase 65 BRIM2 65 confirmatory clinical 65 IMPROVE IT 65 RE LY 65 trastuzumab DM1 T DM1 65 multicenter randomized controlled 65 Xelox 65 Phase Ib II 65 ENESTnd 65 unblinding 65 MEND CABG 65 phase IIb 65 randomized controlled Phase 65 neratinib 65 fidaxomicin Phase 3 65 trastuzumab emtansine T DM1 65 lintuzumab 65 galiximab 65 phase IIb study 65 PLCO 65 PSMA ADC 65 EchoCRT 65 ExTRACT TIMI 65 Phase 2b kidney transplant 65 CALGB # [002] 65 placebo controlled Phase 65 subanalysis 64 multicenter clinical 64 HORIZONS AMI trial 64 RECORD1 64 Phase IIB 64 elotuzumab 64 ONTARGET 64 REVIVE Diabetes 64 Prostate Cancer Prevention 64 ADVANCE PD 64 PreCISe 64 TMC# C# 64 randomized multicenter trial 64 sNDA submission 64 crizotinib PF # 64 IMPACT IMmunotherapy 64 oral FTY# 64 Phase #/#a 64 satraplatin Phase 64 enzastaurin 64 double blinded randomized 64 adecatumumab 64 recurrent GBM 64 SYMMETRY trial 64 assessing T DM1 64 randomized discontinuation trial 64 Pharmacokinetic 64 randomized Phase 2b 64 unblind 64 multicenter placebo controlled 64 RE LY ® 64 CLL8 64 pomalidomide 64 nab paclitaxel 64 PRESEPT 64 Phase Ia 64 randomized controlled clinical 64 ROCKET AF 64 multicenter randomized Phase 64 AVERROES 64 NSABP B 64 INCB# [001] 63 HuMax EGFr 63 registrational 63 CHAMPION PLATFORM 63 HCV RESPOND 2 63 phase IIb trial 63 Phase 2a trial 63 MADIT II 63 randomized multicenter Phase III 63 ERSPC 63 tanespimycin 63 EXPLORE Xa 63 Phase 1b trial 63 BR.# 63 viral kinetics 63 PRECiSE 63 GRAVITAS trial 63 randomized controlled multicenter 63 GAMMAGARD 63 riociguat 63 SWOG 63 LUMINATE 63 AVAiL 63 EURIDIS 63 pharmacokinetic PK study 63 BOLDER II 63 treatment naive genotype 63 rALLy trial 63 PARTNER Trial 63 vismodegib 63 landmark ATHENA 63 Phase 1b clinical 63 SIMPADICO 63 XL# SAR# 63 TG MV 63 EmbraceAC 63 dose escalation Phase 63 EORTC 63 phase IIb III 63 GLP toxicology studies 63 TELCYTA 63 Pivotal Phase III 63 AIR CF2 63 ACRIN 63 dose escalation phase 63 brivaracetam 63 cediranib 63 Phase 2b study 63 prospective multicenter randomized 63 ABSORB trial 63 PRIMO CABG2 63 GSK# [001] 63 Onrigin 63 pertuzumab 62 APPRAISE 62 placebo controlled clinical 62 ALN VSP Phase 62 Intervention Effectiveness 62 trastuzumab DM1 62 IMA# 62 prospectively defined 62 PROSTVAC ® 62 Phase IIa trial 62 AVOREN 62 UPLYSO 62 NCIC CTG 62 EDEMA3 62 Clinical Antipsychotic Trials 62 FOLFIRI chemotherapy 62 ZACTIMA 62 phase Ib clinical 62 TASKi2 62 ganetespib 62 neoadjuvant 62 ASTEROID 62 Phase Ib 62 evaluating Actimmune 62 AIR2 Trial 62 CHAMPION PCI 62 MIVI TRUST 62 NEVO RES 62 metastatic hormone refractory 62 Ceflatonin 62 multicenter prospective 62 MelaFind pivotal 62 tesmilifene 62 TroVax 62 TAXUS IV 62 Phase III placebo controlled 62 ARBITER 6 62 Amrubicin 62 VADT 62 BARI 2D 62 unblinded 62 oral Xeloda 62 CRLX# 62 ACTIVE W 62 prospective multicentre 62 Phase III AFFIRM 62 docetaxel chemotherapy 62 evaluating mipomersen 62 CUSTOM II 62 pharmacokinetic PK 62 GOUT 62 prospective multicenter 62 NSABP C 62 SPIRIT III 62 fidaxomicin Phase 62 pharmacokinetic pharmacodynamic 62 relapsed MM 62 fosbretabulin 62 Phase III ADT 62 pharmacodynamic effects 62 Multicenter Automatic Defibrillator Implantation 62 ACCORD Lipid 61 Phase 1b 61 PROTECT AF 61 NEO3 61 multicenter multinational 61 PIX# [002] 61 Azedra 61 Edge STudy 61 Phase IIIb study 61 Phase 2b trial 61 ISEL 61 blinded randomized placebo controlled 61 MGd 61 elacytarabine 61 EOquin TM 61 registrational Phase 61 TOLAMBA 61 Randomized Phase II 61 CTRC AACR San Antonio 61 multicenter randomized clinical 61 EDEMA4 61 lumiliximab 61 HER2 positive metastatic breast 61 Prostate Lung Colorectal 61 PANVAC VF 61 Aflibercept 61 multicenter trials 61 preclinical efficacy 61 teriflunomide 61 CATIE AD 61 HYVET 61 Phase #b/#a 61 iniparib 61 YONDELIS 61 registrational trial 61 refractory CLL 61 OvaRex MAb 61 IMPACT DCM 61 ataluren 61 ENDEAVOR IV clinical 61 CLIRS 61 LibiGel Phase III 61 PEARL SC 61 dose escalation trial 61 ENDEAVOR II 61 dose cohort 61 ADAGIO study 61 alvespimycin 61 MVax R 61 phase 2a 61 prospective randomized controlled 61 Phase III HEAT 61 standard chemotherapy regimen 61 Cloretazine ® 61 PROactive study 61 mg/m2 cohort 61 IIa trial 61 figitumumab 61 T DM1 61 ELACYT 61 PROTECT II 61 CoFactor 61 pharmacokinetics PK 61 RE LY trial 61 Phase IIIb 61 MEND CABG II 61 Phase 1a 61 Aplidin 61 evaluating tivozanib 61 subcutaneous PRO 61 GALNS 61 Omnitarg 61 EndoTAG TM -1 61 PXD# 61 neoadjuvant treatment 61 TACI Ig 61 gemcitabine carboplatin 61 aflibercept 61 Taxotere ® 61 relapsed refractory multiple myeloma 61 budesonide MMX 61 huC# DM4 61 multicenter Phase III 61 mapatumumab 61 blinded randomized 61 intratumoural 61 thorough QT 61 TAXUS V 61 Quinamed 61 ACCEDE 61 Dendreon Provenge 61 MIRCERA 61 ELCAP 61 AIR CF1 61 AVASTIN 61 Dacogen injection 61 CLORETAZINE TM VNP#M 61 SCD HeFT 61 R# #mg BID 60 Carotid Revascularization Endarterectomy vs. 60 iPrEx 60 bepotastine besilate nasal spray 60 prospective randomized placebo 60 IL# PE#QQR 60 randomized multicenter 60 REVIVE TA 60 Vitaxin 60 sunitinib 60 CIMZIA ™ 60 Sibutramine Cardiovascular Outcomes 60 Phase 1b clinical trials 60 Ophena TM 60 Screening Trial DMIST 60 evaluating REVLIMID 60 PREVENT IV 60 Plicera 60 BETAS 60 PROPEL trial 60 ASCO GI 60 TLK# 60 active comparator 60 NEUVENGE 60 pegylated interferon alfa 2b 60 Solorel TM 60 PROVENGE sipuleucel T 60 Randomized Phase 60 Multicenter Phase 60 dosing cohorts 60 nonclinical studies 60 Phase III randomized controlled 60 Phenoptin 60 ANCHOR trial 60 Zevalin consolidation 60 APEX AMI 60 controlled multicenter Phase 60 Virulizin ® 60 Phase 2a clinical 60 TASKi3 60 remission CR 60 COMFORT II 60 relapsed MCL 60 Mylotarg 60 PCI ExTRACT TIMI 60 Betaferon ® 60 placebo controlled randomized 60 ixabepilone 60 PTK ZK 60 randomized blinded 60 Phase IIB clinical 60 mCRC patients 60 ZYBRESTAT fosbretabulin 60 Screening Trial 60 SYNTAX trial 60 ACUITY trial 60 OVATURE 60 BLA filing 60 arzoxifene 60 Viramidine 60 Novartis Zometa 60 HyQ 60 ICON7 60 adecatumumab MT# 60 Tarceva TM 60 HGS ETR2 60 Thorough QT 60 APTIVUS 60 afatinib 60 Initiated Phase 60 NEVO 60 Phase 2b 60 virus HCV protease inhibitor 60 PRE SURGE 60 GRNVAC1 60 Phase IIa trials 60 ORENCIA ® 60 midstage clinical 60 olaparib 60 Allovectin 7 ® 60 XmAb# 60 Zenvia Phase III 60 multicenter randomized placebo controlled 60 COPERNICUS 60 Phase III Psoriasis 60 BRAF inhibitor 60 Phase 2a 60 vidofludimus 60 Targretin 60 Degarelix 60 PEG SN# 60 ELOXATIN 60 ENDEAVOR clinical 60 Pegasys plus Copegus 60 CRp 60 CALERIE 60 metastatic HRPC 60 adjuvant colon cancer 60 DEB# 60 Phase #/#a trial 60 MAA submission 60 SAR# [004] 60 Pivotal Phase 60 ponatinib 60 KRAS status 60 OLYMPIA registry 60 low dose cytarabine 60 Group B CALGB 60 rALLy 60 RRMS patients 60 BLA submission 60 ASCEND HF 60 RSR# 60 RIO Lipids 60 metastatic renal cell 60 midstage trials 60 BLOOM DM 59 interferon gamma 1b 59 ongoing Phase IIIb 59 XELOX 59 sunitinib malate 59 TAXUS VI 59 PRECISE trial 59 ZOLINZA 59 Randomized controlled 59 #nd EORTC NCI 59 trabectedin 59 sustained virologic response 59 pazopanib 59 clinical pharmacology studies 59 cetuximab Erbitux 59 daily Infergen 59 metastatic CRC 59 Ereska 59 Randomized Evaluation 59 Sprycel dasatinib 59 trastuzumab Herceptin R 59 Board DSMB 59 blinatumomab 59 confirmatory Phase III 59 CLARITY TIMI 59 Arzerra TM 59 farletuzumab 59 glufosfamide 59 Phase #b/#a clinical 59 Afatinib 59 preclinical pharmacokinetic 59 TRANSFORMS 59 IMPROVE HF 59 ORACLE MS 59 Initiate Phase 59 TRITON TIMI 59 MADIT CRT trial 59 abiraterone acetate 59 HGS# 59 efficacy endpoint 59 evaluable subjects 59 MAGE A3 59 TORISEL 59 ASA# 59 HORIZONS AMI 59 randomized Phase 59 Subgroup analysis 59 aclidinium 59 PEG IFN 59 MyVax R 59 talabostat 59 temsirolimus 59 Genz # 59 NCCTG N# 59 zanolimumab 59 pivotal Phase III 59 Tovaxin Phase IIb 59 Ophena 59 ASSERT trial 59 DAPT 59 Ixempra 59 Aryplase 59 HPTN 59 Pharmacokinetic PK 59 forodesine 59 eltrombopag 59 budesonide foam 59 omacetaxine mepesuccinate 59 tarenflurbil 59 Ceplene/IL-2 59 Combination REOLYSIN R 59 CCR5 mAb 59 Xyotax 59 EGFR TKI 59 Oncotype DX colon cancer 59 Phase III 59 Ozarelix 59 severe hypercholesterolemia 59 peginesatide 59 Androxal TM 59 dirucotide 59 recurrent malignant glioma 59 CIMZIA TM 59 Solorel 59 Ocrelizumab 59 GVAX 59 secondary efficacy endpoints 59 eliglustat tartrate 59 Telcyta 59 tipranavir 59 resminostat 59 Phase IIb trials 59 Pemetrexed 59 Torisel 59 LymphoStat B 59 Femara letrozole 59 OPT CHF 59 Gynecologic Oncology Group 59 Phase IIa clinical 59 LAF# 59 Teriflunomide 59 imetelstat 59 refractory chronic lymphocytic 59 CR# vcMMAE 59 Cervista HPV HR 59 relapsing multiple sclerosis 59 VNP#M 59 DAPT Study 59 Phase III pivotal 59 EMPHASIS HF trial 59 APEX PD 59 Tesmilifene 59 Phase III ThermoDox 59 CAPRIE 59 Phase IIb clinical 59 Phase III clinical 59 Multicenter 59 azilsartan medoxomil 59 recurrent glioma 59 Asentar 59 oral deforolimus 59 RTOG 59 ASCO abstract 59 PreCISe study 59 ON #.Na 59 genotypic resistance 59 HuMax CD4 59 CIMZIA TM certolizumab pegol 59 Glufosfamide 59 Folfox 59 CA9 SCAN 59 Trastuzumab DM1 59 Renal Cell Carcinoma RCC 59 EDEMA3 trial 59 Vectibix panitumumab 59 NCCTG 59 COSIRA trial 59 NLX P# 59 Val HeFT 59 Arranon 59 Traficet EN 59 substudy 58 Phase III TRIST 58 CAPRISA 58 REVLIMID lenalidomide 58 trastuzumab Herceptin 58 FIRMAGON R 58 APF# Phase 58 tocilizumab 58 tramiprosate Alzhemed TM 58 subgroup analyzes 58 eprotirome 58 Active Ulcerative Colitis 58 Augment Injectable 58 Phase III randomized 58 PRECISE 58 RSD# oral 58 adjuvant endocrine therapy 58 SUTENT ® 58 OvaRex ® MAb 58 pharmacodynamic PD 58 metreleptin 58 Complete Response 58 iclaprim 58 Digital Mammographic Imaging 58 REALITY Trial 58 Campath alemtuzumab 58 zalutumumab 58 oxymorphone ER 58 Phase IIA 58 velaglucerase alfa 58 postoperative chemotherapy 58 dacetuzumab 58 TBC# 58 WHIMS 58 regorafenib 58 decitabine 58 Avastin bevacizumab 58 Phase III ALLEGRO 58 INSPIRE Trial Phase III 58 nonrandomized 58 ritonavir boosted 58 ACTEMRA TM 58 ATTAIN 58 darunavir ritonavir 58 ALSYMPCA 58 MAQC 58 dose proportionality 58 AACR NCI EORTC 58 placebo controlled clinical trials 58 Antiviral Activity 58 Targretin capsules 58 ADMIRE HF 58 COU AA 58 IMGN# 58 recurrent glioblastoma multiforme 58 KRAS mutations occur 58 Phase 2b monotherapy 58 RESTORE CLI 58 JAK inhibitor 58 BEZ# 58 RADIANT 58 AZILECT ® 58 Acute Ischemic Stroke 58 metastatic castration resistant 58 tipifarnib 58 PREGNANT Study 58 intradermal injections 58 velafermin 58 bevirimat Study 58 MADIT CRT 58 Kahalalide F 58 romidepsin 58 prospective randomized multicenter 58 bevacizumab Avastin 58 samalizumab 58 OncoVEX GM CSF 58 Capesaris 58 Brentuximab Vedotin SGN 58 lorcaserin Phase 58 Phase 2b clinical 58 abstracts summarizing 58 blinded randomized controlled 58 Velcade bortezomib 58 Trofex 58 PF # [002] 58 GENASIS trial 58 disease progression TTP 58 tremelimumab 58 sapacitabine 58 budesonide MMX Phase III 58 Prospective Randomized 58 Temsirolimus 58 Liraglutide Effect 58 MIVI III 58 Zemplar Capsules 58 mRCC 58 angiographic outcomes 58 EMPHASIS HF 58 BAY #-# 58 PegIFN RBV 58 iniparib BSI 58 ZD# [001] 58 antiangiogenic therapy 58 DSMB 58 elagolix 58 clinical endpoints 58 PROMACTA 58 vernakalant hydrochloride 58 Hormone Refractory Prostate Cancer 58 Proellex TM 58 StemEx R 58 senicapoc 58 Canvaxin 58 baminercept 58 nilotinib 58 nitazoxanide 58 sorafenib Nexavar 58 SVR# 58 ECASS 58 Trial PCPT 58 MADIT 58 noninferiority 58 Hexvix 58 CANCIDAS 58 pain palliation 58 neoadjuvant chemotherapy 58 ThermoDox ® clinical 58 PrevOnco 58 double blinded placebo 58 Intervention Effectiveness CATIE 58 Orathecin 58 sustained virological response 58 refractory multiple myeloma 58 ER CHOP 58 PERSEUS clinical program 58 Pertuzumab 58 pharmacokinetic PK profile 58 placebo controlled dose escalation 58 teduglutide 58 pharmacodynamic properties 58 Long Lesion 58 Xcellerated T Cells 58 relapsing remitting MS RRMS 58 NP2 Enkephalin 58 DMIST 58 PROSTVAC VF 58 atrasentan 58 ruboxistaurin 58 prospective nonrandomized 58 Nexavar sorafenib 58 confirmatory Phase 3 58 Stenting Trial CREST 58 ofatumumab 58 CCX# 58 enoximone 58 RECIST Response Evaluation Criteria 58 dosing cohort 58 PMA submission 58 custirsen 58 masitinib 58 PROCHYMAL 58 NATRECOR ® 58 canakinumab 58 ruxolitinib 58 tolevamer 58 HuMax CD# 58 varespladib 58 castration resistant prostate cancer 58 Kaplan Meier analysis 58 Proxinium TM 58 Aurexis 58 BOLDER 58 NVA# 58 Dr. McHutchison 58 National Surgical Adjuvant 58 ORMD 58 Vilazodone 58 Randomized Double blind 58 relapsed myeloma 58 Xeloda ® 58 Pharmacodynamic 58 glatiramer acetate 58 statistically significant efficacy 58 Neoadjuvant 58 abiraterone 58 Corlux 58 antitumour activity 58 davunetide intranasal AL 58 Phase IIb trial 58 MVax 58 Arzerra ofatumumab 57 investigational protease inhibitor 57 TYKERB 57 bendamustine 57 Cloretazine 57 DSMB recommended 57 CURRENT OASIS 7 57 KYNAPID 57 HF ACTION 57 rALLy clinical trial 57 BioNumerik 57 Bezielle 57 FOLFIRI 57 ARCOXIA 57 Matrix Phase 2b 57 Raloxifene STAR 57 vandetanib 57 Cloretazine R VNP#M 57 HGS ETR1 57 MabCampath 57 goserelin 57 Tocosol Paclitaxel 57 Tanespimycin 57 dasatinib 57 confirmatory 57 TRIST study 57 Imprime PGG 57 Aptivus ® 57 peginterferon alfa 2b 57 RG# [001] 57 Virologic 57 motesanib diphosphate 57 recurrent NSCLC 57 Hedgehog antagonist 57 epoetin alpha 57 Neuvenge 57 CHARM Added 57 Panitumumab 57 treatment naïve genotype 57 evaluating T DM1 57 multicentre prospective 57 QUASAR validation study 57 NASDAQ CXSP announced 57 KRAS mutation 57 Pirfenidone 57 ONCONASE R 57 Phase IIb 57 ATTRACT 57 huN# DM1 57 Phase III Pivotal 57 Xanafide 57 NCT# ClinicalTrials.gov 57 MyVax personalized immunotherapy 57 Ceflatonin ® 57 LEXIVA r 57 oral rivaroxaban 57 REMINYL ® 57 CLIRS trial 57 Erbitux cetuximab 57 TMC# [002] 57 cisplatin vinorelbine 57 GSK# [002] 57 SNT MC# 57 vemurafenib 57 docetaxel Taxotere R 57 PROPEL 57 ATAC Arimidex Tamoxifen Alone 57 liposomal doxorubicin 57 evaluating Prochymal 57 NASDAQ CYTK announced 57 BiovaxID Phase 57 HoFH 57 denufosol 57 dose cohorts 57 IMC #B 57 L MTP PE 57 Gattex 57 Zybrestat 57 Phase IIb randomized 57 masked placebo controlled 57 gadobutrol 57 fluvastatin 57 palifosfamide 57 ORBIT II 57 Orazol 57 ENRICH trial 57 virologic 57 initiated Phase Ib 57 ABSORB clinical 57 Alocrest 57 FOLOTYN ® 57 IND submission 57 PROVENGE ® 57 Phase IIa 57 Xinlay 57 icatibant 57 Pivotal Trial 57 Phase 1b dose escalation 57 GeoVax vaccine 57 metastatic renal cell carcinoma 57 Phase Ib IIa 57 telaprevir dosing 57 lapatinib 57 Phase Ib clinical trials 57 NATRECOR R 57 Saforis 57 Vicriviroc 57 QLT# 57 OncoVex 57 telaprevir dosed 57 plus dexamethasone 57 YERVOY 57 aclidinium bromide 57 ticagrelor Brilinta 57 IIa clinical 57 BiTE antibody MT# 57 Phase III confirmatory 57 PENNVAX B 57 oral methylnaltrexone 57 phase III ACCLAIM 57 sorafenib tablets 57 Phase 2b RESTORE CLI 57 #mg ATC 57 initiate Phase 1b 57 evaluating Vectibix 57 paclitaxel Taxol R 57 UroVysion 57 multicentre 57 Truvada tablets 57 PEARL HF 57 ACCOMPLISH 57 carboplatin paclitaxel 57 virologic response 57 valopicitabine 57 secondary efficacy endpoint 57 ARDIS 57 AACR #st Annual Meeting 57 BLP# Liposome Vaccine 57 RIGScan CR 57 deforolimus 57 Allovectin 7 57 pegylated liposomal doxorubicin 57 OncoVEX 57 PRoFESS 57 Hepatocellular Carcinoma HCC 57 USpella 57 trials RCTs 57 #rd Annual CTRC 57 comparing alemtuzumab 57 GEM OS1 57 colesevelam HCl 57 granted Ortec 57 Platelet Inhibition 57 midstage studies 57 evaluating Nexavar 57 PIX# trial 57 VELCADE melphalan 57 CINQUIL 57 refractory acute myeloid 57 EXPAREL ™ 57 randomized multicentre 57 INC# 57 R#/MEM # 57 balsalazide tablet 57 Prospective Multicenter 57 Solid Tumors 57 mITT population 57 ID NCT# 57 clinical trial 57 BrachySil 57 FAME Study 57 antiviral efficacy 57 BNC# 57 HeFT 57 panitumumab 57 PACCE trial 57 ATACAND 57 CRMD# 57 adjuvant trastuzumab 57 amrubicin 57 Triapine R 57 mCRC 57 Asthma Intervention 57 ACCORD COPD 57 APOPTONE 57 Advaxis Phase 57 Phase III Clinical Trial 57 Sipuleucel T 57 safety tolerability pharmacokinetic 57 Sym# 57 Jevtana 57 Phase Ib IIa clinical 57 Tumor Response 57 CR nPR 57 doxorubicin docetaxel 57 AEG# 57 Clinical Outcomes Utilizing Revascularization 57 KRN# 57 Telintra 57 Echocardiographic 57 KNS # 57 receptor tyrosine kinase inhibitor 57 CHARISMA trial 57 BrachySil TM 57 label multicenter Phase 57 TRA 2P 57 GeoVax HIV AIDS 57 ALGRX 57 OPTIMIZE